Aikium is Unlocking the Undruggable Proteome
Using the Worlds First AI-Powered Trillion-Molecule Screening
Yotta-ML²: Where AI Meets the Proteome
Screening AI-designed ultra-large libraries with unprecedented precision
Unmatched Scale: 1,000x library capacity vs. traditional methods
Target-Agnostic: From G protein-coupled receptors (GPCRs) to Ion Channels and beyond
Rapid Development: Achieving therapeutic breakthroughs in months, not years
Yotta-ML2 the platform that enables Yotta-scale (1024) machine learning (ML) on massive libraries by combining the world’s only AI-Driven trillion-protein mRNA display for large proteins and patented generative AI based on protein language models
Latest News
November 2024
Why we are Different
Binders to Differentiated Regions: Targeting areas antibodies and small molecules cannot
High-Impact Partnerships: Collaborating with leading pharma and academic institutions
Proven Team: Leaders from NVIDIA, Harvard, 10X Genomics, NIH and the Wyss Institute
Advisory Board
-
Dr. Kevin Yang
DEEP LEARNING FOR PROTEINS EXPERT
Microsoft Research
-
Dr. Leena Das-Young
CEO Caliber Bio, Ex-Pfizer
-
Dr. Nina Bhardwaj
Mt. Sinai, New York
-
Dr. Tracy Handel
Univ. of California, San Diego
-
Prof. George Church
Harvard, MIT, Wyss
-
Dr. Mark Lebwohl
Mt. Sinai, New York
-
Dr. Nicolas Gaudenzio
INSERM, Genoskin
-
Prof. Lawrence Stern
U Mass Med School, MIT
-
Dr. Mette Rosenkilde
Univ. of Copenhagen, Bainan, Synklino, Antag Tx
-
Dr. Tarjei Mikkelsen
CTO, Arsenal Bio
Founders
Investors
Aikium is Calling!
Join the foundational team pioneering a transformative platform with the power to shape the future of medicine. Together, we aim to deliver 100 breakthrough therapies within the next decade.
